1 EXHIBIT 10.19 LICENSE AND JOINT DEVELOPMENT AGREEMENT BETWEEN NIMCO, ALTEA AND SPECTRX This License and Joint Development Agreement is made as of the 1st day of March, 1996 (Effective Date), by and between SpectRx, Inc. ("SRX"), a Delaware...License and Joint Development Agreement • February 27th, 1997 • Spectrx Inc • Delaware
License and Joint Development Agreement on NC-6300/K-912 with KowaLicense and Joint Development Agreement • October 21st, 2016
On October 21, 2016, NanoCarrier accepted the proposal from Kowa Company, Ltd. (President & CEO: Yoshihiro Miwa; “Kowa”) to cancel the agreement on licensing for the exclusive manufacture and marketing and joint development of Epirubicin Micelle (NC-6300/K-912) worldwide originally executed on September 26, 2011.
EXHIBIT 10.17BLicense and Joint Development Agreement • April 1st, 2002 • Spectrx Inc • Electromedical & electrotherapeutic apparatus • Delaware
License and Joint Development Agreement on Novel Biliary Tract Cancer TreatmentLicense and Joint Development Agreement • April 24th, 2019
Ohara Pharmaceutical Co., Ltd. (Head office: Shiga, Japan; CEO: Seiji Ohara; hereinafter, “Ohara”) has entered into a license and joint development agreement with J-Pharma Co., Ltd, dated April 25, 2019 regarding the novel compound JPH203. (Head office: Kanagawa, Japan; Representative Director and Chairman: Hitoshi Endou, M.D., Ph.D; Representative Director and President: Masuhiro Yoshitake; hereinafter, “J-Pharma”).
